Key facts: Carlsmed Q3 Revenue +65%; Outlook and Analyst Targets Raised
Carlsmed (CARL) reported Q3 revenue of $21.6M, up 65% YoY, exceeding estimates. Loss per share was $0.45. The company raised its fiscal 2026 revenue guidance to $78M–$80M. All five analysts rate CARL Buy, with raised price targets averaging $22.
How this was made
The 30-second read
Why it matters
The earnings beat and raised guidance have already prompted analyst upgrades, suggesting short‑term upside potential.
Market read
First‑report earnings and guidance raise for a micro‑cap; analysts have already moved targets, indicating immediate market relevance.
What to watch
Potential dilution from future capital raises and the company's cash runway are not addressed in the brief.
Background
Carlsmed (CARL) is a micro‑cap listed on NASDAQ, focused on medical device technology.
Ticker impact
Q3 revenue rose 65% YoY to $21.6M and fiscal 2026 revenue guidance was raised to $78‑$80M; analysts lifted price targets.
upward pressure as the market prices in higher revenue expectations and raised targets
The earnings beat and guidance raise are fresh primary disclosures; analysts have already increased targets, indicating near‑term buying interest.
Market effects
Boosts the small‑cap biotech/health‑tech sector as a positive earnings surprise.
Limited to U.S. micro‑cap investors; no broader regional effect.
Minimal global impact beyond niche investors.
Counterpoint
The revenue base remains tiny; the guidance raise may be overly optimistic and could lead to disappointment if growth stalls.
Key entities
- CompanyCarlsmed
NASDAQ‑listed medical‑device firm reporting Q3 results.
- AnalystBTIG
Raised price target to $26.
- AnalystTruist
Raised price target to $23.
- AnalystNeedham
Raised price target to $22.
